January 09, 2023
Search
95 Result(s)
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
September 02, 2022
First approval for SPEVIGO® to treat GPP flares
January 03, 2024
Partnership for new liver disease treatments with Ribo
October 02, 2023
Phase 1 start of treatment for Geographic Atrophy patients
Gastrointestinal Cancers
Brightline-2 trial launch in biliary tract and pancreatic cancers
Find out more about the Brightline-2 trial and our commitment to people living with biliary tract and pancreatic cancers.
Fostering Science
On the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund (BIVF) acquires minority stakes in biotech start-ups exploring promising therapies and technologies, and even supports the majority before and during their founding.
September 11, 2020
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
October 14, 2020
Expanded alliance with OBT advances cancer immunology pipeline
Science Stories
Targeting MDM2-p53 in cancer: The story of brigimadlin
Our perseverance and passion for science led to the discovery of brigimadlin, our MDM2-p53 antagonist. It is being clinically investigated as a potential treatment for dedifferentiated liposarcoma, a rare cancer with significant unmet needs.
Article
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
September 17, 2020
Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor
January 09, 2024
Kicking off 2024 with five new R&D partnerships
October 02, 2023
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
December 19, 2022
New digital Tx collab with Click
April 14, 2021
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
December 07, 2020
Collaboration with Proxygen on Molecular Glue Degraders
January 12, 2021
Collaboration with Enara Bio on Cancer Immunotherapies
Lung Cancer
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential targeted immunotherapy for DLL3-positive small cell lung cancer and neuroendocrine carcinomas.
March 11, 2024
New partnership to develop schizophrenia treatments
Cancer
Brightline-1 trial launch in rare sarcoma
Find out more from Mehdi Lahmar, Clinical Program Leader for Oncology, about our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).
More Health: For People & Animals
Advancing health: Our impactful R&D investments
Discover how we’re investing in innovation for a sustainable tomorrow
Science & Innovation
Transforming Science Day
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
July 09, 2020